Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
Rita G. Kansal(University of Tennessee Health Science Center), Noah Richardson(University of Tennessee Health Science Center), Indira Neeli(University of Tennessee Health Science Center), Saleem Khawaja(University of Tennessee Health Science Center), Damian Chamberlain(University of Tennessee Health Science Center), Marium Ghani(University of Tennessee Health Science Center), Qurat-ul-ain Ghani(University of Tennessee Health Science Center), Louisa Balázs(University of Tennessee Health Science Center), Šárka Beranová-Giorgianni(University of Tennessee Health Science Center), Francesco Giorgianni(University of Tennessee Health Science Center), James N. Kochenderfer(National Cancer Institute), Tony N. Marion(University of Tennessee Health Science Center), Lorraine M. Albritton(University of Tennessee Health Science Center), Marko Radic(University of Tennessee Health Science Center)
Cited by 353Open Access
Abstract
B cells and reduced disease in naive autoimmune mice, indicating that disease control was cell-mediated. Sustained B cell depletion with CD19-targeted CAR T cell immunotherapy is a stable and effective strategy to treat murine lupus, and its effectiveness should be explored in clinical trials for lupus.
Related Papers
No related papers found
Powered by citation graph analysis